Narendra Modi reviews India's COVID-19 vaccine strategy, prioritisation of population groups

-

New Delhi: Prime Minister Narendra Modi on Friday held a meeting to review India's COVID-19 vaccination strategy in which issues like prioritisation of population groups, including health and other frontline workers, and tech platform for rolling out the vaccine were discussed.

Modi tweeted that the meeting discussed important issues related to progress of vaccine development, regulatory approvals and procurement.

"Reviewed various issues like prioritisation of population groups, reaching out to HCWs (health care workers), cold-chain infrastructure augmentation, adding vaccinators and tech platform for vaccine roll-out," he said.

The prime minister directed that a time-bound plan be laid out for speedy regulatory clearances and timely procurement for early roll-out of the vaccination drive when a vaccine becomes available, an official statement later said.

Database, cold chain augmentation and transportation mechanisms are being readied, with digital platform for vaccine delivery and monitoring being prepared and tested in consultation with all stakeholders, it said.

Modi also reviewed the aspects of emergency use authorisation and for manufacture and procurement of medicine.

As the results of phase-III trials from national and international vaccine arrive, our robust and independent regulators will speedily and rigorously examine these for according authorisation for use, the statement said.

Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II.

Countries such as Bangladesh, Myanmar, Qatar, Bhutan, Switzerland, Bahrain, Austria and South Korea have shown keen interest in partnering for vaccine development of Indian vaccines and use, the statement said.

In the meeting, the prime minister appreciated the efforts of innovators, scientists, academicians and pharma companies to develop vaccines and directed that every effort should be made to facilitate research, development and manufacturing of the vaccine.

In an effort to administer the vaccine at the first available opportunity, database of healthcare and frontline workers, augmentation of cold chains and procurement of syringes and needles among other items are in advanced stages of preparation, it said.

The vaccination supply chain is being enhanced and non-vaccine supplies are being escalated. Medical and nursing students and faculty will be involved in training and implementation of the vaccination programme.

Every step is being steadily put in place to ensure that vaccines reach every location and person according to the prioritisation principles, the statement said.

"The prime minister has directed to work in collaboration with all reputed national and international institutions and regulators to ensure the rigour and highest global standards in Indian research and manufacturing," it said.

The National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) in consultation with state governments and all relevant stakeholders has accelerated the implementation of vaccination of priority groups in the first phase, the statement said.

"The digital platform for vaccine administration and distribution is prepared and test runs underway in partnership with state and district level stakeholders," it said.

The government has provided an assistance of Rs 900 crore under 'Covid Suraksha Mission' to support research and development of the COVID-19 vaccination.

Appreciating the comprehensive efforts on vaccine development, Modi also emphasised that given the persisting pandemic scenario there is no place for any relaxation in preventive measures such as wearing masks, keeping distance and ensuring hygiene.

The meeting was attended by the principal secretary to the prime minister, cabinet secretary, member (health) NITI Aayog, principal scientific advisor, secretary health, DG ICMR, officers of the PMO, and secretaries of related departments of the government of India, the statement said.



from Firstpost India Latest News https://ift.tt/2KuClsv
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

120 flights delayed, 30 trains running late; Delhi fog & cold wave continue to give shiver to travellers

-
Arrival and departure of 120 flights, both domestic and international, to Delhi airport were affected due to dense fog and cold wave conditions on Wednesday, according to Delhi Airport FIDS (Flight Information Display System). As per the Delhi Airport FIDS, a total of 53 flights, including 21 domestic arrivals, 16 domestic departures, 13 international departures and three international arrivals scheduled are cancelled and not operating due to fog and other operational reasons from and to Indira Gandhi International (IGI) Airport in the national capital on 17 January. #WATCH | Delhi: Several flight operations delayed at IGI airport due to low visibility amid fog. pic.twitter.com/hG1DUKllEt — ANI (@ANI) January 17, 2024 Visuals from the Delhi airport showed passengers waiting outside, checking update of their scheduled flights. There were also some people waiting for flight of their families, friends and loved ones to arrive, which got delayed due to fog. #WATCH | Delhi | Pas
Read more